AVE8134 is a new synthetic PPARα agonist that has excited many researchers given its anti-angiogenesis and anti-tumour properties, as well as its high PPARα affinity and low hepatotoxicity [18, 19]. The gene discussed is PPARA; the disease is neoplasm.